Roivant Sciences Ltd.

Roivant is a biopharmaceutical company that focuses on accelerating the development and commercialization of medicines across diverse therapeutic areas. The company organizes its operations through specialized, nimble subsidiary companies known as “Vants,” while also incubating early-stage discovery ventures and complementary health technology businesses. Its clinical pipeline centers on therapeutic candidates such as brepocitinib, an oral small-molecule dual inhibitor targeting inflammatory and immune conditions; IMVT-1402, a fully human monoclonal antibody directed against IgG-mediated autoimmune indications; and mosliciguat, an inhaled formulation under evaluation for pulmonary vascular disorders. Roivant targets patient populations suffering from severe autoimmune, dermatological, rheumatological, and respiratory conditions where current medical options remain inadequate.

The company advances its clinical programs within the United States, conducting registrational trials and pursuing regulatory submissions across specialized clinical networks. Beyond therapeutics development, Roivant supports discovery and software-driven initiatives that integrate computational workflows into biopharma processes. The company does not operate commercial retail stores, and the provided text does not state its corporate headquarters location.

Summary of the business section of Roivant Sciences's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of March 31, 2026, we and our subsidiaries had approximately 721 full-time employees, including 659 in the U.S.”